Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How do you counsel pre-menopausal breast cancer patients about birth control?
Does recommendations differ during vs off treatment; hormone positive vs negative disease?
Related Questions
What modifications, if any, will you make for your use of dose dense taxane chemotherapy in early stage breast cancer with the end-of-study PANTHER results?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
In a patient with BRCA2 mutation and contralateral axillary recurrence of ER+ IDC with an ESR1 CCDC170 fusion on NGS testing, would you use standard adjuvant AI therapy or consider adjuvant SERD therapy (fulvestrant/elacestrant)?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
Do you have concerns about the generalizability of Oncotype testing/Mammaprint testing in making chemotherapy decisions for non-Caucasian women?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Would you offer adjuvant endocrine therapy to a patient with a history of ER-positive DCIS, s/p bilateral mastectomy, now with chest wall recurrence of DCIS four year later?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?